{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:28:25Z","timestamp":1793755705752,"version":"4.6.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11060-026-05821-y","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:58:52Z","timestamp":1791925132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions"],"prefix":"10.1007","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4285-1773","authenticated-orcid":false,"given":"Truman J.","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-3678","authenticated-orcid":false,"given":"Shameel","family":"Shafqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-1519","authenticated-orcid":false,"given":"Sani H.","family":"Kizilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2768-2913","authenticated-orcid":false,"given":"Cristiane M.","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"5821_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fonc.2019.01547","volume":"9","author":"W Yu","year":"2019","unstructured":"Yu W, Zhang L, Wei Q, Shao A (2019) O(6)-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy. Front Oncol 9:1547. https:\/\/doi.org\/10.3389\/fonc.2019.01547","journal-title":"Front Oncol"},{"key":"5821_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.dnarep.2019.04.007","volume":"78","author":"B Kaina","year":"2019","unstructured":"Kaina B, Christmann M (2019) DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. DNA Repair 78:128\u2013141. https:\/\/doi.org\/10.1016\/j.dnarep.2019.04.007","journal-title":"DNA Repair"},{"key":"5821_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1215\/15228517-2008-090","volume":"11","author":"GJ Kitange","year":"2009","unstructured":"Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11:281\u2013291. https:\/\/doi.org\/10.1215\/15228517-2008-090","journal-title":"Neuro Oncol"},{"key":"5821_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"5821_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-8817(85)90034-3","volume":"145","author":"DB Yarosh","year":"1985","unstructured":"Yarosh DB (1985) The role of O6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat Res 145:1\u201316. https:\/\/doi.org\/10.1016\/0167-8817(85)90034-3","journal-title":"Mutat Res"},{"key":"5821_CR6","doi-asserted-by":"publisher","unstructured":"Karlsson M, Zhang C, M\u00e9ar L, Zhong W, Digre A, Katona B, Sj\u00f6stedt E, Butler L, Odeberg J, Dusart P, Edfors F, Oksvold P, von Feilitzen K, Zwahlen M, Arif M, Altay O, Li X, Ozcan M, Mardinoglu A, Fagerberg L, Mulder J, Luo Y, Ponten F, Uhl\u00e9n M, Lindskog C (2021) A single-cell type transcriptomics map of human tissues. Sci Adv 7. https:\/\/doi.org\/10.1126\/sciadv.abh2169","DOI":"10.1126\/sciadv.abh2169"},{"key":"5821_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0921-8777(94)90074-4","volume":"314","author":"A Rasouli-Nia","year":"1994","unstructured":"Rasouli-Nia A, Sibghat U, Mirzayans R, Paterson MC, Day RS 3rd (1994) On the quantitative relationship between O6-methylguanine residues in genomic DNA and production of sister-chromatid exchanges, mutations and lethal events in a Mer- human tumor cell line. Mutat Res 314:99\u2013113. https:\/\/doi.org\/10.1016\/0921-8777(94)90074-4","journal-title":"Mutat Res"},{"key":"5821_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41467-017-01355-0","volume":"8","author":"J Cheng","year":"2017","unstructured":"Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, B\u00f8rresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingj\u00e6rde OC, Moreau Y, Van Loo P (2017) Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. Nat Commun 8:1221. https:\/\/doi.org\/10.1038\/s41467-017-01355-0","journal-title":"Nat Commun"},{"key":"5821_CR9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA (2018) The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer 18:696\u2013705. https:\/\/doi.org\/10.1038\/s41568-018-0060-1","journal-title":"Nat Rev Cancer"},{"key":"5821_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/1535-7163.1127.3.9","volume":"3","author":"MD Bacolod","year":"2004","unstructured":"Bacolod MD, Johnson SP, Pegg AE, Dolan ME, Moschel RC, Bullock NS, Fang Q, Colvin OM, Modrich P, Bigner DD, Friedman HS (2004) Brain tumor cell lines resistant to O6-benzylguanine\/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther 3:1127\u20131135","journal-title":"Mol Cancer Ther"},{"key":"5821_CR11","doi-asserted-by":"publisher","first-page":"v256","DOI":"10.1093\/neuonc\/noaf201.1017","volume":"27","author":"V Huynh","year":"2025","unstructured":"Huynh V, Isaacson M, Zhang D, Kizilbash S, Raghunathan A, Trejo-Lopez J, Mendoza CZ, Ida C (2025) PATH-65. MGMT homozygous deletion: A rare potential pitfall for MGMT promoter methylation testing in CNS tumors. Neuro Oncol 27:v256\u2013v256. https:\/\/doi.org\/10.1093\/neuonc\/noaf201.1017","journal-title":"Neuro Oncol"},{"key":"5821_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00401-018-1905-0","volume":"136","author":"D Stichel","year":"2018","unstructured":"Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, Reifenberger G, Weller M, Hanggi D, Wick W, Herold-Mende C, Westphal M, Brandner S, Pfister SM, Capper D, Sahm F, von Deimling A (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793\u2013803. https:\/\/doi.org\/10.1007\/s00401-018-1905-0","journal-title":"Acta Neuropathol"},{"key":"5821_CR13","first-page":"793","volume":"59","author":"M Esteller","year":"1999","unstructured":"Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793\u2013797","journal-title":"Cancer Res"},{"key":"5821_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00401-011-0803-5","volume":"121","author":"DS Malley","year":"2011","unstructured":"Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121:651\u2013661. https:\/\/doi.org\/10.1007\/s00401-011-0803-5","journal-title":"Acta Neuropathol"},{"key":"5821_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00401-012-1016-2","volume":"124","author":"P Bady","year":"2012","unstructured":"Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, McDonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547\u2013560. https:\/\/doi.org\/10.1007\/s00401-012-1016-2","journal-title":"Acta Neuropathol"},{"key":"5821_CR16","doi-asserted-by":"publisher","first-page":"1342114","DOI":"10.3389\/fonc.2024.1342114","volume":"14","author":"R Weber","year":"2024","unstructured":"Weber R, Weller M, Reifenberger G, Vasella F (2024) Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells. Front Oncol 14:1342114. https:\/\/doi.org\/10.3389\/fonc.2024.1342114","journal-title":"Front Oncol"},{"key":"5821_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11060-024-04708-0","volume":"169","author":"Y Yousefi","year":"2024","unstructured":"Yousefi Y, Nejati R, Eslahi A, Alizadeh F, Farrokhi S, Asoodeh A, Mojarrad M (2024) Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT). J Neurooncol 169:129\u2013135. https:\/\/doi.org\/10.1007\/s11060-024-04708-0","journal-title":"J Neurooncol"},{"key":"5821_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/jnen\/nlag044","volume":"85","author":"T Do","year":"2026","unstructured":"Do T, Abdullaev Z, Aldape K, Quezado HC, Singh M, Wu O, Ida Z C (2026) A Uniform MGMT Promoter Methylation Analysis of Over 15,000 Central and Peripheral Nervous System Tumors. J Neuropathol Exp Neurol 85:631. https:\/\/doi.org\/10.1093\/jnen\/nlag044","journal-title":"J Neuropathol Exp Neurol"},{"key":"5821_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.17879\/freeneuropathology-2024-5345","volume":"5","author":"DE Reuss","year":"2024","unstructured":"Reuss DE, Schrimpf D, Cherkezov A, Suwala AK, Lausova T, Snuderl M, Capper D, Sill M, Jones DTW, Pfister SM, Sahm F, von Deimling A (2024) Heterogeneity of DNA methylation profiles and copy number alterations in 10782 adult-type glioblastomas, IDH-wildtype. Free Neuropathol 5:7. https:\/\/doi.org\/10.17879\/freeneuropathology-2024-5345","journal-title":"Free Neuropathol"},{"key":"5821_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff R-O (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"5821_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP (2017) Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 376:1027\u20131037. https:\/\/doi.org\/10.1056\/NEJMoa1611977","journal-title":"N Engl J Med"},{"key":"5821_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ijc.26083","volume":"129","author":"J Felsberg","year":"2011","unstructured":"Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, L\u00f6ffler M, Weller M, Reifenberger G, Tonn JC (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129:659\u2013670. https:\/\/doi.org\/10.1002\/ijc.26083","journal-title":"Int J Cancer"},{"key":"5821_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JCO.19.00367","volume":"38","author":"K Draaisma","year":"2020","unstructured":"Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer R, Watts C, McAbee J, Angelopoulos N, Gorlia T, Golfinopoulos V, Kros JM, Verhaak RGW, Bours V, van den Bent MJ, McDermott U, Robe PA, French PJ (2020) Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. J Clin Oncol 38:81\u201399. https:\/\/doi.org\/10.1200\/JCO.19.00367","journal-title":"J Clin Oncol"},{"key":"5821_CR24","doi-asserted-by":"publisher","unstructured":"Noren H, Pelofsky G, Suffren B, Mittelman L, Yohn C, Twyman A, Febres-Aldana CA, Abramyan A, Sertil A, D\u2019Amico RS, Sherman JH, Vojnic M (2026) Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge. J Neurooncol 179. https:\/\/doi.org\/10.1007\/s11060-026-05778-y","DOI":"10.1007\/s11060-026-05778-y"},{"key":"5821_CR25","doi-asserted-by":"publisher","first-page":"112913","DOI":"10.1016\/j.ejca.2023.05.002","volume":"189","author":"C Hertler","year":"2023","unstructured":"Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, Chinot O, Ducray F, Roth P, McDonald K, Hau P, Hottinger AF, Reijneveld J, Schnell O, Marosi C, Glantz M, Darlix A, Lombardi G, Krex D, Glas M, Reardon DA, van den Bent M, Lefranc F, Herrlinger U, Razis E, Carpentier AF, Phillips S, Rud\u00e0 R, Wick A, Tabouret E, Meyronet D, Maurage CA, Rushing E, Rapkins R, Bumes E, Hegi M, Weyerbrock A, Aregawi D, Gonzalez-Gomez C, Pellerino A, Klein M, Preusser M, Bendszus M, Golfinopoulos V, von Deimling A, Gorlia T, Wen PY, Reifenberger G, Weller M (2023) Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders\u2019 Collaborative Consortium (EORTC 1419). Eur J Cancer 189:112913. https:\/\/doi.org\/10.1016\/j.ejca.2023.05.002","journal-title":"Eur J Cancer"},{"key":"5821_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707\u2013715. https:\/\/doi.org\/10.1016\/S1470-2045(12)70164-X","journal-title":"Lancet Oncol"},{"key":"5821_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/s1470-2045(12)70265-6","volume":"13","author":"A Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916\u2013926. https:\/\/doi.org\/10.1016\/s1470-2045(12)70265-6","journal-title":"Lancet Oncol"},{"key":"5821_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nop020","volume":"12","author":"AL Rivera","year":"2010","unstructured":"Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116\u2013121. https:\/\/doi.org\/10.1093\/neuonc\/nop020","journal-title":"Neuro Oncol"},{"key":"5821_CR29","doi-asserted-by":"publisher","first-page":"v26","DOI":"10.1093\/neuonc\/noae144.079","volume":"26","author":"A Lassman","year":"2024","unstructured":"Lassman A, Alexander B, Berry D, Buxton M, Cavenee W, Colman H, De Groot J, Ellingson B, Gordon G, Hyddmark EMV, Khasraw M, Lim M, Mellinghoff I, Mikkelsen T, Perry J, Powell A, Sulman E, Tanner K, Weller M, Yung WKA, Blondin N, Brenner A, Butt O, de la Fuente MI, Drappatz J, Iwamoto F, Kim L, Lee E, Mantica M, Nabors B, Newton H, Schiff D, Walbert T, Weathers S, Cloughesy T, Wen PY (2024) OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB. Neuro Oncol 26:v26\u2013v27. https:\/\/doi.org\/10.1093\/neuonc\/noae144.079","journal-title":"Neuro Oncol"},{"key":"5821_CR30","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1200\/JCO.2024.42.16_suppl.2005","volume":"42","author":"TF Groot JFd, Cloughesy","year":"2024","unstructured":"Groot JFd, Cloughesy TF, Berry DA, Buxton MB, Colman H, Ellingson BM, Gordon GB, Lassman AB, Lim M, Mellinghoff IK, Sulman EP, Weller M, Wen PY, Hyddmark EMV, Mikkelsen T, Owen SP, Mason WP, Drappatz J, Blondin NA, Perry JR (2024) Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. J Clin Oncol 42:2005\u20132005. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2005","journal-title":"J Clin Oncol"},{"key":"5821_CR31","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1200\/jco.23.00493","volume":"41","author":"R Rahman","year":"2023","unstructured":"Rahman R, Trippa L, Lee EQ, Arrillaga-Romany I, Fell G, Touat M, McCluskey C, Wiley J, Gaffey S, Drappatz J, Welch MR, Galanis E, Ahluwalia MS, Colman H, Nabors LB, Hepel J, Elinzano H, Schiff D, Chukwueke UN, Beroukhim R, Nayak L, McFaline-Figueroa JR, Batchelor TT, Rinne ML, Kaley TJ, Lu-Emerson C, Mellinghoff IK, Bi WL, Arnaout O, Peruzzi PP, Haas-Kogan D, Tanguturi S, Cagney D, Aizer A, Doherty L, Lavallee M, Fisher-Longden B, Dowling S, Geduldig J, Watkinson F, Pisano W, Malinowski S, Ramkissoon S, Santagata S, Meredith DM, Chiocca EA, Reardon DA, Alexander BM, Ligon KL, Wen PY (2023) Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol 41:5524\u20135535. https:\/\/doi.org\/10.1200\/jco.23.00493","journal-title":"J Clin Oncol"},{"key":"5821_CR32","doi-asserted-by":"publisher","first-page":"viii117","DOI":"10.1093\/neuonc\/noae165.0451","volume":"26","author":"W Wick","year":"2024","unstructured":"Wick W, Lanz L-M, Wick A, Harting I, Dettmer S, Suwala A, Ketter R, Tabatabai G, Seliger C, Glas M, Burger M, Timmer M, Ringel F, Mildenberger I, Schulz-Schaefer W, Renovanz M, Bendszus M, Sahm F, Platten M, Kessler T (2024) CTNI-85. FINAL RESULTS FROM N2M2\/NOA-20. Neuro Oncol 26:viii117\u2013viii117. https:\/\/doi.org\/10.1093\/neuonc\/noae165.0451","journal-title":"Neuro Oncol"},{"key":"5821_CR33","doi-asserted-by":"publisher","first-page":"690036","DOI":"10.3389\/fonc.2021.690036","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Kim MM, Wahl DR, Lawrence TS, Parmar H, Cao Y (2021) Survival Prediction Analysis in Glioblastoma With Diffusion Kurtosis Imaging. Front Oncol 11:690036. https:\/\/doi.org\/10.3389\/fonc.2021.690036","journal-title":"Front Oncol"},{"key":"5821_CR34","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","volume":"26","author":"AA Brandes","year":"2008","unstructured":"Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192\u20132197. https:\/\/doi.org\/10.1200\/JCO.2007.14.8163","journal-title":"J Clin Oncol"},{"key":"5821_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/s0317167100009628","volume":"37","author":"P Sanghera","year":"2010","unstructured":"Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M, Lam K, Davey P, Tsao MN (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37:36\u201342. https:\/\/doi.org\/10.1017\/s0317167100009628","journal-title":"Can J Neurol Sci"},{"key":"5821_CR36","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/jco.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak DP, de Groot J, Gilbert MR, Huang R, Lassman AB, Mehta M, Molinaro AM, Preusser M, Rahman R, Shankar LK, Stupp R, Villanueva-Meyer JE, Wick W, Macdonald DR, Reardon DA, Vogelbaum MA, Chang SM (2023) RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 41:5187\u20135199. https:\/\/doi.org\/10.1200\/jco.23.01059","journal-title":"J Clin Oncol"},{"key":"5821_CR37","doi-asserted-by":"publisher","first-page":"vdae159","DOI":"10.1093\/noajnl\/vdae159","volume":"6","author":"VK Yadav","year":"2024","unstructured":"Yadav VK, Mohan S, Agarwal S, de Godoy LL, Rajan A, Nasrallah MP, Bagley SJ, Brem S, Loevner LA, Poptani H, Singh A, Chawla S (2024) Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O6-methylguanine-methyltransferase promoter methylation status. Neurooncol Adv 6:vdae159. https:\/\/doi.org\/10.1093\/noajnl\/vdae159","journal-title":"Neurooncol Adv"},{"key":"5821_CR38","doi-asserted-by":"publisher","first-page":"27533","DOI":"10.1038\/s41598-025-08608-9","volume":"15","author":"WS Chen","year":"2025","unstructured":"Chen WS, Fu FX, Cai QL, Wang F, Wang XH, Hong L, Su L (2025) Prediction of MGMT methylation status in glioblastoma patients based on radiomics feature extracted from intratumoral and peritumoral MRI imaging. Sci Rep 15:27533. https:\/\/doi.org\/10.1038\/s41598-025-08608-9","journal-title":"Sci Rep"},{"key":"5821_CR39","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 318:2306\u20132316. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"5821_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jocn.2016.10.042","volume":"36","author":"PA Clark","year":"2017","unstructured":"Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, Robins HI (2017) The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. J Clin Neurosci 36:120\u2013124. https:\/\/doi.org\/10.1016\/j.jocn.2016.10.042","journal-title":"J Clin Neurosci"},{"key":"5821_CR41","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","volume":"393","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann R-D, Krex D, Grauer O, Goldbrunner R, Schnell O, Bahr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schafer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn J-C, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393:678\u2013688. https:\/\/doi.org\/10.1016\/S0140-6736(18)31791-4","journal-title":"Lancet"},{"key":"5821_CR42","unstructured":"A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma (2021). In: National Cancer Institute (ed)"},{"key":"5821_CR43","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/neuonc\/noab039","volume":"23","author":"C Horbinski","year":"2021","unstructured":"Horbinski C, McCortney K, Stupp R (2021) MGMT promoter methylation is associated with patient age and 1p\/19q status in IDH-mutant gliomas. Neuro Oncol 23:858\u2013860. https:\/\/doi.org\/10.1093\/neuonc\/noab039","journal-title":"Neuro Oncol"},{"key":"5821_CR44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00401-020-02194-y","volume":"140","author":"R Banan","year":"2020","unstructured":"Banan R, Stichel D, Bleck A, Hong B, Lehmann U, Suwala A, Reinhardt A, Schrimpf D, Buslei R, Stadelmann C, Ehlert K, Prinz M, Acker T, Schittenhelm J, Kaul D, Schweizer L, Capper D, Harter PN, Etminan N, Jones DTW, Pfister SM, Herold-Mende C, Wick W, Sahm F, von Deimling A, Hartmann C, Reuss DE (2020) Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol 140:569\u2013581. https:\/\/doi.org\/10.1007\/s00401-020-02194-y","journal-title":"Acta Neuropathol"},{"key":"5821_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00401-023-02662-1","volume":"147","author":"M Weller","year":"2024","unstructured":"Weller M, Felsberg J, Hentschel B, Gramatzki D, Kubon N, Wolter M, Reusche M, Roth P, Krex D, Herrlinger U, Westphal M, Tonn JC, Regli L, Maurage CA, von Deimling A, Pietsch T, Le Rhun E, Reifenberger G (2024) Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma. Acta Neuropathol 147:11. https:\/\/doi.org\/10.1007\/s00401-023-02662-1","journal-title":"Acta Neuropathol"},{"key":"5821_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11060-023-04515-z","volume":"166","author":"CJ Kinslow","year":"2024","unstructured":"Kinslow CJ, Siegelin MD, Iwamoto FM, Gallitto M, Neugut AI, Yu JB, Cheng SK, Wang TJC (2024) MGMT promoter methylation in 1p19q-intact gliomas. J Neurooncol 166:73\u201378. https:\/\/doi.org\/10.1007\/s11060-023-04515-z","journal-title":"J Neurooncol"},{"key":"5821_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s1470-2045(25)00614-x","volume":"27","author":"MJ van den Bent","year":"2026","unstructured":"van den Bent MJ, Ghisai SA, Wick W, Sanson M, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Tabouret E, Gill S, Griffin M, Taal W, Rud\u00e0 R, Weller M, McBain C, Reijneveld JC, Enting RH, Tran S, Lesimple T, Kocher M, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Hoogstrate Y, Nuyens S, Golfinopoulos V, Tesileanu CMS, Gorlia T, French P, Baumert BG (2026) Concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u2009\u2013\u200922054): final and exploratory analyses of a randomised, open-label, phase 3 trial. Lancet Oncol 27:45\u201356. https:\/\/doi.org\/10.1016\/s1470-2045(25)00614-x","journal-title":"Lancet Oncol"},{"key":"5821_CR48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/neuonc\/noac014","volume":"24","author":"CMS Tesileanu","year":"2022","unstructured":"Tesileanu CMS, Gorlia T, Golfinopoulos V, French PJ, van den Bent MJ, Group EBT, investigators tC (2022) MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. Neuro Oncol 24:665\u2013667. https:\/\/doi.org\/10.1093\/neuonc\/noac014","journal-title":"Neuro Oncol"},{"key":"5821_CR49","doi-asserted-by":"publisher","first-page":"e214478","DOI":"10.1212\/WNL.0000000000214478","volume":"106","author":"MA Maqbool","year":"2026","unstructured":"Maqbool MA, Jenkins RB, Ida CM, Burns TC, Drucker KL, Kollmeyer TM, Lachance DH, Raghunathan A, Vaubel RA, Giannini C, Decker PA, Eckel-Passow JE, Kizilbash SH (2026) Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma. Neurology 106:e214478. https:\/\/doi.org\/10.1212\/WNL.0000000000214478","journal-title":"Neurology"},{"key":"5821_CR50","doi-asserted-by":"publisher","first-page":"103485","DOI":"10.1016\/j.esmoop.2024.103485","volume":"9","author":"A Dipasquale","year":"2024","unstructured":"Dipasquale A, Franceschi E, Giordano L, Maccari M, Barigazzi C, Di Nunno V, Losurdo A, Persico P, Di Muzio A, Navarria P, Pessina F, Padovan M, Santoro A, Lombardi G, Simonelli M (2024) Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study. Esmo Open 9:103485. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103485","journal-title":"Esmo Open"},{"key":"5821_CR51","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG (2021) Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u2009\u2013\u200922054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22:813\u2013823. https:\/\/doi.org\/10.1016\/S1470-2045(21)00090-5","journal-title":"Lancet Oncol"},{"key":"5821_CR52","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1001\/jamaoncol.2023.0990","volume":"9","author":"CJ Kinslow","year":"2023","unstructured":"Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC (2023) Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy. JAMA Oncol 9:919\u2013927. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0990","journal-title":"JAMA Oncol"},{"key":"5821_CR53","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.1200\/jco.2009.23.6497","volume":"27","author":"W Wick","year":"2009","unstructured":"Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874\u20135880. https:\/\/doi.org\/10.1200\/jco.2009.23.6497","journal-title":"J Clin Oncol"},{"key":"5821_CR54","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1212\/WNL.0b013e3182a95680","volume":"81","author":"W Wick","year":"2013","unstructured":"Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M (2013) Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81:1515\u20131522. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a95680","journal-title":"Neurology"},{"key":"5821_CR55","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/jco.21.02543","volume":"40","author":"AB Lassman","year":"2022","unstructured":"Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, Ashby LS, Taphoorn MJB, Souhami L, Dinjens WNM, Laack NN, Kouwenhoven MCM, Fink KL, French PJ, Macdonald DR, Lacombe D, Won M, Gorlia T, Mehta MP, van den Bent MJ (2022) Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. J Clin Oncol 40:2539\u20132545. https:\/\/doi.org\/10.1200\/jco.21.02543","journal-title":"J Clin Oncol"},{"key":"5821_CR56","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-23-1295","volume":"29","author":"CJ Kinslow","year":"2023","unstructured":"Kinslow CJ, Rae AI, Taparra K, Kumar P, Siegelin MD, Grinband J, Gill BJA, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Horowitz DP, Kachnic LA, Neugut AI, Yu JB, Cheng SK, Wang TJC (2023) MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p\/19q-Codeleted Gliomas. Clin Cancer Res 29:4399\u20134407. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1295","journal-title":"Clin Cancer Res"},{"key":"5821_CR57","unstructured":"(2009) Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p\/19q Co-deleted Anaplastic Glioma or Low Grade Glioma. In: National Cancer I, European Organisation for R, Treatment C, Canadian Cancer Trials G (eds)"},{"key":"5821_CR58","unstructured":"Universit\u00e4tsmedizin M (ed) (2022) Improvement of Functional Outcome for Patients With Newly Diagnosed Grade 2 or 3 Glioma With Co-deletion of 1p\/19q - IMPROVE CODEL: the NOA-18 Trial. Ruhr University of B (eds)"},{"key":"5821_CR59","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","volume":"22","author":"D Sturm","year":"2012","unstructured":"Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fruhwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Durken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425\u2013437. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.024","journal-title":"Cancer Cell"},{"key":"5821_CR60","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/noaf015","volume":"27","author":"E Le Rhun","year":"2025","unstructured":"Le Rhun E, Bink A, Felsberg J, Gramatzki D, Brandner S, Benhamida JK, Wick A, Tonn JC, Mohme M, Tabatabai G, Capper D, Snuderl M, Razis E, Ronellenfitsch MW, Neidert N, Ng HK, Pohl U, Bale T, Quach S, Rieger D, Schuller U, Onken J, Druschler K, Maurage CA, Regli L, Healy E, Graham M, Hortobagyi T, Paine S, Bridges L, Lausova T, Medici V, Sievers P, Schrimpf D, Wick W, Sahm F, Reifenberger G, von Deimling A, Weller M (2025) The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant. Neuro Oncol 27:1519\u20131535. https:\/\/doi.org\/10.1093\/neuonc\/noaf015","journal-title":"Neuro Oncol"},{"key":"5821_CR61","doi-asserted-by":"publisher","first-page":"vdac133","DOI":"10.1093\/noajnl\/vdac133","volume":"4","author":"C Crowell","year":"2022","unstructured":"Crowell C, Mata-Mbemba D, Bennett J, Matheson K, Mackley M, Perreault S, Erker C (2022) Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors. Neurooncol Adv 4:vdac133. https:\/\/doi.org\/10.1093\/noajnl\/vdac133","journal-title":"Neurooncol Adv"},{"key":"5821_CR62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Ruda R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"5821_CR63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","volume":"136","author":"A Reinhardt","year":"2018","unstructured":"Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE, Koelsche C, Huang K, Wefers AK, Hovestadt V, Sill M, Gramatzki D, Felsberg J, Reifenberger G, Koch A, Thomale UW, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Mueller W, Tuffaha MSA, Paulus W, Hess K, Brokinkel B, Schittenhelm J, Monoranu CM, Kessler AF, Loehr M, Buslei R, Deckert M, Mawrin C, Kohlhof P, Hewer E, Olar A, Rodriguez FJ, Giannini C, NageswaraRao AA, Tabori U, Nunes NM, Weller M, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hanggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Jones DTW, von Deimling A, Capper D (2018) Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations. Acta Neuropathol 136:273\u2013291. https:\/\/doi.org\/10.1007\/s00401-018-1837-8","journal-title":"Acta Neuropathol"},{"key":"5821_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2019.00041","volume":"9","author":"P Daniel","year":"2019","unstructured":"Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS (2019) Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities. Front Oncol 9:41. https:\/\/doi.org\/10.3389\/fonc.2019.00041","journal-title":"Front Oncol"},{"key":"5821_CR65","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, Ligon KL (2020) Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580:517\u2013523. https:\/\/doi.org\/10.1038\/s41586-020-2209-9","journal-title":"Nature"},{"key":"5821_CR66","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1038\/s41467-020-17717-0","volume":"11","author":"B Oldrini","year":"2020","unstructured":"Oldrini B, Vaquero-Siguero N, Mu Q, Kroon P, Zhang Y, Galan-Ganga M, Bao Z, Wang Z, Liu H, Sa JK, Zhao J, Kim H, Rodriguez-Perales S, Nam DH, Verhaak RGW, Rabadan R, Jiang T, Wang J, Squatrito M (2020) MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nat Commun 11:3883. https:\/\/doi.org\/10.1038\/s41467-020-17717-0","journal-title":"Nat Commun"},{"key":"5821_CR67","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5858\/arpa.2021-0295-CP","volume":"146","author":"DJ Brat","year":"2022","unstructured":"Brat DJ, Aldape K, Bridge JA, Canoll P, Colman H, Hameed MR, Harris BT, Hattab EM, Huse JT, Jenkins RB, Lopez-Terrada DH, McDonald WC, Rodriguez FJ, Souter LH, Colasacco C, Thomas NE, Yount MH, van den Bent MJ, Perry A (2022) Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Arch Pathol Lab Med 146:547\u2013574. https:\/\/doi.org\/10.5858\/arpa.2021-0295-CP","journal-title":"Arch Pathol Lab Med"},{"key":"5821_CR68","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/neuonc\/noab163","volume":"23","author":"ME Hegi","year":"2021","unstructured":"Hegi ME, Ichimura K (2021) MGMT testing always worth an emotion. Neuro Oncol 23:1417\u20131418. https:\/\/doi.org\/10.1093\/neuonc\/noab163","journal-title":"Neuro Oncol"},{"key":"5821_CR69","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/neuonc\/noy132","volume":"21","author":"A Mansouri","year":"2019","unstructured":"Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G (2019) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol 21:167\u2013178. https:\/\/doi.org\/10.1093\/neuonc\/noy132","journal-title":"Neuro Oncol"},{"key":"5821_CR70","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/1078-0432.Ccr-21-4283","volume":"28","author":"CMS Tesileanu","year":"2022","unstructured":"Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rud\u00e0 R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van Cheung IWFJ, Golfinopoulos KJ, Baumert V, Gorlia BG, French T, van den Bent PJ MJ (2022) Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clin Cancer Res 28:2527\u20132535. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-4283","journal-title":"Clin Cancer Res"},{"key":"5821_CR71","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/neuonc\/noab105","volume":"23","author":"S Brandner","year":"2021","unstructured":"Brandner S, McAleenan A, Kelly C, Spiga F, Cheng H-Y, Dawson S, Schmidt L, Faulkner CL, Wragg C, Jefferies S, Higgins JPT, Kurian KM (2021) MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neuro Oncol 23:1457\u20131469. https:\/\/doi.org\/10.1093\/neuonc\/noab105","journal-title":"Neuro Oncol"},{"key":"5821_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12883-024-03605-3","volume":"24","author":"D Gibson","year":"2024","unstructured":"Gibson D, Vo AH, Lambing H, Bhattacharya P, Tahir P, Chehab FF, Butowski N (2024) A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]. BMC Neurol 24:103. https:\/\/doi.org\/10.1186\/s12883-024-03605-3","journal-title":"BMC Neurol"},{"key":"5821_CR73","doi-asserted-by":"publisher","first-page":"61916","DOI":"10.18632\/oncotarget.11322","volume":"7","author":"V Quillien","year":"2016","unstructured":"Quillien V, Lavenu A, Ducray F, Joly M-O, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D (2016) Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. Oncotarget 7:61916\u201361929. https:\/\/doi.org\/10.18632\/oncotarget.11322","journal-title":"Oncotarget"},{"key":"5821_CR74","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/nop\/npz039","volume":"7","author":"A Malmstrom","year":"2020","unstructured":"Malmstrom A, Lysiak M, Kristensen BW, Hovey E, Henriksson R, Soderkvist P (2020) Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma. Neurooncol Pract 7:68\u201376. https:\/\/doi.org\/10.1093\/nop\/npz039","journal-title":"Neurooncol Pract"},{"key":"5821_CR75","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1750-3639.2008.00153.x","volume":"18","author":"M Preusser","year":"2008","unstructured":"Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou M-F, Diserens A-C, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520\u2013532. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00153.x","journal-title":"Brain Pathol"},{"key":"5821_CR76","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1002\/cncr.27392","volume":"118","author":"V Quillien","year":"2012","unstructured":"Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussi\u00e8re M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118:4201\u20134211. https:\/\/doi.org\/10.1002\/cncr.27392","journal-title":"Cancer"},{"key":"5821_CR77","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2353\/jmoldx.2008.070169","volume":"10","author":"I Vlassenbroeck","year":"2008","unstructured":"Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M, Flamion B, DiGuiseppi J, Bierau K, Hegi ME (2008) Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10:332\u2013337. https:\/\/doi.org\/10.2353\/jmoldx.2008.070169","journal-title":"J Mol Diagn"},{"key":"5821_CR78","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/ajcp\/aqx073","volume":"148","author":"CM Ida","year":"2017","unstructured":"Ida CM, Butz ML, Jenkins RB, Sarkaria JN, Kitange GJ, Giannini C, Kipp BR (2017) Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma: An Alternative Detection Method for a Heterogeneous Process. Am J Clin Pathol 148:296\u2013307. https:\/\/doi.org\/10.1093\/ajcp\/aqx073","journal-title":"Am J Clin Pathol"},{"key":"5821_CR79","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jmoldx.2025.10.005","volume":"27","author":"M Isaacson","year":"2025","unstructured":"Isaacson M, Milosevic D, Schneider A, Pazdernik V, Kizilbash S, Maqbool M, Lachance D, Ida C (2025) ST002. Analytical and Clinical Validation of a Droplet Digital Polymerase Chain Reaction (ddPCR) Assay for Detection of O-6- Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation. J Mol Diagn 27:S1\u2013S206. https:\/\/doi.org\/10.1016\/j.jmoldx.2025.10.005","journal-title":"J Mol Diagn"},{"key":"5821_CR80","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-023-01680-0","volume":"11","author":"M McCord","year":"2023","unstructured":"McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, Parker S, Baczkowski J, Jennings L, Walshon J, McCortney K, Galbraith K, Zhang H, Lukas RV, Stupp R, Dixit K, Kumthekar P, Heimberger AB, Snuderl M, Horbinski C (2023) Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. Acta Neuropathol Commun 11:175. https:\/\/doi.org\/10.1186\/s40478-023-01680-0","journal-title":"Acta Neuropathol Commun"},{"key":"5821_CR81","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2353\/jmoldx.2007.060167","volume":"9","author":"T Mikeska","year":"2007","unstructured":"Mikeska T, Bock C, El-Maarri O, H\u00fcbner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, B\u00fcttner R, Pietsch T, Waha A (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368\u2013381. https:\/\/doi.org\/10.2353\/jmoldx.2007.060167","journal-title":"J Mol Diagn"},{"key":"5821_CR82","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5414\/np300730","volume":"33","author":"M Preusser","year":"2014","unstructured":"Preusser M, Berghoff AS, Manzl C, Filipits M, Weinh\u00e4usel A, Pulverer W, Dieckmann K, Widhalm G, W\u00f6hrer A, Knosp E, Marosi C, Hainfellner JA (2014) Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clin Neuropathol 33:6\u201314. https:\/\/doi.org\/10.5414\/np300730","journal-title":"Clin Neuropathol"},{"key":"5821_CR83","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jmoldx.2015.11.009","volume":"18","author":"P Bady","year":"2016","unstructured":"Bady P, Delorenzi M, Hegi ME (2016) Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. J Mol Diagn 18:350\u2013361. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.11.009","journal-title":"J Mol Diagn"},{"key":"5821_CR84","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ijc.27385","volume":"131","author":"G Reifenberger","year":"2012","unstructured":"Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, Weller M (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342\u20131350. https:\/\/doi.org\/10.1002\/ijc.27385","journal-title":"Int J Cancer"},{"key":"5821_CR85","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/neuonc\/noaa033","volume":"22","author":"A Wick","year":"2020","unstructured":"Wick A, Kessler T, Platten M, Meisner C, Bamberg M, Herrlinger U, Felsberg J, Weyerbrock A, Papsdorf K, Steinbach JP, Sabel M, Vesper J, Debus J, Meixensberger J, Ketter R, Hertler C, Mayer-Steinacker R, Weisang S, Bolting H, Reuss D, Reifenberger G, Sahm F, von Deimling A, Weller M, Wick W (2020) Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro Oncol 22:1162\u20131172. https:\/\/doi.org\/10.1093\/neuonc\/noaa033","journal-title":"Neuro Oncol"},{"key":"5821_CR86","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.prp.2017.10.007","volume":"213","author":"L Wang","year":"2017","unstructured":"Wang L, Li Z, Liu C, Chen L, Liu L, Hu Z, Zhao L, Lu D, Teng L (2017) Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. Pathol Res Pract 213:1489\u20131493. https:\/\/doi.org\/10.1016\/j.prp.2017.10.007","journal-title":"Pathol Res Pract"},{"key":"5821_CR87","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/1078-0432.CCR-18-3181","volume":"25","author":"ME Hegi","year":"2019","unstructured":"Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M (2019) MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clin Cancer Res 25:1809\u20131816. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3181","journal-title":"Clin Cancer Res"},{"key":"5821_CR88","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.bjc.6605127","volume":"101","author":"J Dunn","year":"2009","unstructured":"Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124\u2013131. https:\/\/doi.org\/10.1038\/sj.bjc.6605127","journal-title":"Br J Cancer"},{"key":"5821_CR89","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40478-019-0745-z","volume":"7","author":"J Radke","year":"2019","unstructured":"Radke J, Koch A, Pritsch F, Schumann E, Misch M, Hempt C, Lenz K, L\u00f6bel F, Paschereit F, Heppner FL, Vajkoczy P, Koll R, Onken J (2019) Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. Acta Neuropathol Commun 7:89. https:\/\/doi.org\/10.1186\/s40478-019-0745-z","journal-title":"Acta Neuropathol Commun"},{"key":"5821_CR90","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/nop\/npac070","volume":"10","author":"M Torre","year":"2022","unstructured":"Torre M, Wen PY, Iorgulescu JB (2022) The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients. Neurooncol Pract 10:126\u2013131. https:\/\/doi.org\/10.1093\/nop\/npac070","journal-title":"Neurooncol Pract"},{"key":"5821_CR91","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","volume":"26","author":"ME Hegi","year":"2024","unstructured":"Hegi ME, Oppong FB, Perry JR, Wick W, Henriksson R, Laperriere NJ, Gorlia T, Malmstr\u00f6m A, Weller M (2024) No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients. Neuro Oncol 26:1867\u20131875. https:\/\/doi.org\/10.1093\/neuonc\/noae108","journal-title":"Neuro Oncol"},{"key":"5821_CR92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40478-021-01134-5","volume":"9","author":"S Siller","year":"2021","unstructured":"Siller S, Lauseker M, Karschnia P, Niyazi M, Eigenbrod S, Giese A, Tonn J-C (2021) The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. Acta Neuropathol Commun 9:35. https:\/\/doi.org\/10.1186\/s40478-021-01134-5","journal-title":"Acta Neuropathol Commun"},{"key":"5821_CR93","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/neuonc\/noz011","volume":"21","author":"A Wenger","year":"2019","unstructured":"Wenger A, Ferreyra Vega S, Kling T, Bontell TO, Jakola AS, Caren H (2019) Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. Neuro Oncol 21:616\u2013627. https:\/\/doi.org\/10.1093\/neuonc\/noz011","journal-title":"Neuro Oncol"},{"key":"5821_CR94","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S1525-1578(23)00249-0","volume":"25","author":"M Isaacson","year":"2023","unstructured":"Isaacson M, Milosevic D, Schneider A, Kipp B, Ida C (2023) TT052. Bisulfite Conversion DNA Recovery Rate by Droplet Digital Polymerase Chain Reaction. J Mol Diagn 25:S1\u2013S165. https:\/\/doi.org\/10.1016\/S1525-1578(23)00249-0","journal-title":"J Mol Diagn"},{"key":"5821_CR95","doi-asserted-by":"publisher","first-page":"e12984","DOI":"10.1111\/nan.12984","volume":"50","author":"S Halldorsson","year":"2024","unstructured":"Halldorsson S, Nagymihaly RM, Patel A, Brandal P, Panagopoulos I, Leske H, Lund-Iversen M, Sahm F, Vik-Mo EO (2024) Accurate and comprehensive evaluation of O6-methylguanine-DNA methyltransferase promoter methylation by nanopore sequencing. Neuropathol Appl Neurobiol 50:e12984. https:\/\/doi.org\/10.1111\/nan.12984","journal-title":"Neuropathol Appl Neurobiol"},{"key":"5821_CR96","doi-asserted-by":"publisher","unstructured":"Tasci E, Zhuge Y, Zhang L, Ning H, Cheng JY, Miller RW, Camphausen K, Krauze AV (2025) Radiomics and AI-Based Prediction of MGMT Methylation Status in Glioblastoma Using Multiparametric MRI: A Hybrid Feature Weighting Approach. Diagnostics (Basel) 15. https:\/\/doi.org\/10.3390\/diagnostics15101292","DOI":"10.3390\/diagnostics15101292"},{"key":"5821_CR97","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1002\/cam4.3217","volume":"9","author":"S Richard","year":"2020","unstructured":"Richard S, Tachon G, Milin S, Wager M, Karayan-Tapon L (2020) Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma. Cancer Med 9:6344\u20136353. https:\/\/doi.org\/10.1002\/cam4.3217","journal-title":"Cancer Med"},{"key":"5821_CR98","doi-asserted-by":"publisher","first-page":"e58206","DOI":"10.1371\/journal.pone.0058206","volume":"8","author":"J Ramalho-Carvalho","year":"2013","unstructured":"Ramalho-Carvalho J, Pires M, Lisboa S, Gra\u00e7a I, Rocha P, Barros-Silva JD, Savva-Bordalo J, Maur\u00edcio J, Resende M, Teixeira MR, Honavar M, Henrique R, Jer\u00f3nimo C (2013) Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations. PLoS ONE 8:e58206. https:\/\/doi.org\/10.1371\/journal.pone.0058206","journal-title":"PLoS ONE"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05821-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:04:33Z","timestamp":1793754273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05821-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5821"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05821-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"8 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"16"}}